Cumulative neodymium:YAG laser rates after bag-in-the-lens and lens-in-the-bag intraocular lens implantation: Comparative study
Accepted 30 July 2006.
Purpose
To study the cumulative neodymium:YAG (Nd:YAG) laser rate after bag-in-the-lens implantation (Morcher 89A) and lens-in-the-bag implantation (Morcher 92S) of 2 intraocular lenses (IOLs) of the same biomaterial.
Setting
Department of Ophthalmology, University Hospital of Antwerp, Edegem, Belgium.
Methods
This study comprised 100 eyes of 87 patients who had the bag-in-the-lens IOL implantation between January 2000 and August 2004. The postoperative follow-up ranged between 17 and 72 months. One hundred eyes of 94 patients of the same age and with the same follow-up period received the lens-in-the-bag IOL. The cumulative Nd:YAG laser frequency rates in both groups were calculated, and the cumulative incidence rates were defined by Kaplan-Meier survival analysis.
Results
No Nd:YAG laser capsulotomy was performed in eyes having bag-in-the-lens IOL implantation. A laser capsulotomy was performed in 20 eyes having lens-in-the-bag IOL implantation; the cumulative frequency in this group was 2% at 1 year and 20% at 71 months, with a plateau beginning at 42 months. The cumulative incidence rate of Nd:YAG posterior capsulotomy was approximately 2% at 1 year, increasing to approximately 28% at 42 months.
Conclusions
The cumulative Nd:YAG laser rate after bag-in-the-lens implantation was zero. A zero rate has not been reported with lens-in-the-bag implantation of an IOL of the same biomaterial or of other biomaterials, as published in the literature. Thus, it can be concluded that the bag-in-the-lens implantation technique has 100% effectiveness against posterior capsule opacification.
From the Department of Ophthalmology, University Hospital Antwerp, Edegem, Belgium
Corresponding author: Marie-José Tassignon, Department of Ophthalmology, University Hospital Antwerp, Wilrijkstraat 10, B-2650 Edegem, Belgium.
Presented at the ASCRS Symposium on Cataract, IOL and Refractive Surgery, Washington, D.C., April 2005.
Dr. Tassignon has a proprietary interest patented under reference number 1830/2D739-EPO—US 6,027,531. No other author has a financial or proprietary interest in any method or material mentioned.
ABSTRACT